Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apadenoson vs Adenosine for SPECT MPI in CAD
NCT00380198Phase 3Terminated
- Sponsor
- Forest Laboratories
- Start
- Jul 2006
- Primary completion
- Nov 2006
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of apadenoson in coronary artery disease (CAD) (2 arms), sponsored by Forest Laboratories. Primary endpoint: Agreement between MPI Summed Stress Scores. Started Jul 2006; status: terminated.
02
Drugs
apadenoson
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT00380198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00380198.